Attorney Jessica Paluch-Hoerman, founder of TruLaw, has over 28 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Question: Why was Depo Provera banned in 1978?
Answer: Depo Provera was banned in 1978 by the FDA because studies linked the drug to breast cancer in beagle dogs. The FDA denied approval for contraceptive use at that time due to these safety concerns.
On this page, we’ll answer this question in further depth, Depo Provera linked to increased health risks for women, Depo Provera’s disproportionate impact on women in developing countries, and much more.
The Food and Drug Administration banned Depo Provera as a contraceptive in the United States in 1978 following a four-year study that demonstrated alarming health risks.
This decision was influenced by the drug’s association with mammary tumors in beagles and cervical cancer in humans.
The ban remained in place until 1992, when the FDA finally approved Depo Provera for contraceptive use in the United States.
Laboratory animals exposed to the drug developed various forms of cancer, prompting immediate regulatory action despite heavy lobbying from the manufacturer Upjohn.
The FDA determined that the potential dangers of this injectable birth control method outweighed its benefits as a contraceptive option for American women.
If you or someone you love has suffered serious health complications after receiving Depo Provera injections, you may qualify to seek compensation for your injuries.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine your eligibility to join others in filing a Depo Provera Lawsuit today.
Our Depo Provera attorney at TruLaw is dedicated to supporting clients through the process of filing a Depo Provera lawsuit.
With extensive experience in dangerous drugs cases, Jessica Paluch-Hoerman and our partner law firms work with litigation leaders and medical experts to prove how Depo Provera injections caused you harm.
TruLaw focuses on securing compensation for medical expenses, bone density treatment costs, pain and suffering, and other damages resulting from your Depo Provera injuries.
We understand the physical and emotional toll that Depo Provera complications have on your life and provide the personalized guidance you need when seeking justice.
Meet our lead Depo Provera attorney:
At TruLaw, we believe financial concerns should never stand in the way of justice.
That’s why we operate on a contingency fee basis—with this approach, you only pay legal fees after you’ve been awarded compensation for your injuries.
If you or a loved one has suffered health problems after receiving Depo Provera injections, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Depo Provera Lawsuit today.
The FDA’s repeated rejection of Depo Provera for contraceptive use between 1967 and 1983 represents one of the most contentious regulatory battles in pharmaceutical history.
Despite being available for non-contraceptive purposes in the United States since 1959 and approved as a contraceptive in numerous other countries by the 1970s, the FDA maintained its prohibition on Depo Provera shot use for birth control based on alarming safety data.
This decade-spanning prohibition occurred while the drug’s manufacturer, Upjohn Company, simultaneously conducted widespread testing on vulnerable populations internationally, creating a troubling dichotomy where Depo Provera patients in developing nations were exposed to a drug deemed too dangerous for American women by U.S. regulators according to findings from studies published in the Journal of the American Medical Association.
The pivotal evidence against Depo Provera came from laboratory studies where animals exposed to medroxyprogesterone acetate developed significant cancer risks.
When the drug was tested in 1973, FDA scientists noted that beagles receiving the drug demonstrated escalated risks of breast cancer, though they initially argued that the drug had such a “small patient population, that limited clinical trials with informed patient consent” would be permitted.
This hesitant stance hardened following more comprehensive results from the seven-year beagle study completed in 1975, which proved decisive in the 1978 rejection.
Additional animal studies revealed serious health risks associated with Depo Provera:
The eventual approval of Depo Provera in 1992 and the later development of Depo SubQ Provera (approved in 2004) followed decades of international use and further research that reconsidered the cancer risk data.
Safety concerns never fully dissipated, with the FDA requiring black box warnings about bone density loss for both formulations and recommendations against long-term use exceeding two years.
These persistent safety questions have fueled ongoing debate about whether regulators struck the appropriate balance between making effective contraceptive options available while adequately protecting Depo Provera patients from potential long-term health risks.
The first application for Depo Provera’s approval as a contraceptive came in 1967, but by 1974, the FDA issued its initial rejection based on preliminary safety data.
This decision was solidified in 1978 following concerning results from a seven-year study involving 36 beagle dogs, where two animals developed malignant breast tumors after receiving the hormone injection.
The beagle studies were particularly significant because the breed had become the FDA’s standard animal model for testing drug safety following the thalidomide tragedy, making these findings difficult to dismiss.
The regulatory saga continued with a rare “Public Board of Inquiry” convened by the FDA in 1983, where gender and power dynamics played central roles in negotiations between scientists, physicians, patients, and advocacy groups.
Throughout this process, the National Women’s Health Network emerged as a formidable opponent to approval, raising pointed questions about both the drug’s safety profile and the ethics of testing practices that disproportionately targeted vulnerable populations.
Their objections highlighted fundamental concerns about informed consent and coercion in the clinical trials, particularly those conducted on poor women, rural women, and third-world women who often lacked access to alternative contraceptive options or complete information about potential risks.
If you or a loved one has suffered health problems after receiving Depo Provera injections, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Depo Provera Lawsuit today.
The controversial history of Depo Provera reveals a pharmaceutical intervention that received multiple FDA rejections between 1967 and 1992 before finally gaining approval as a contraceptive option in the United States.
Initially approved only for cancer treatment, the injectable containing medroxyprogesterone acetate faced significant regulatory hurdles due to safety concerns, including cancer risks in animal studies, which delayed its contraceptive approval for 25 years despite widespread international use.
Recent scientific research published by the National Library of Medicine has uncovered additional serious health concerns for Depo Provera users.
The initial FDA rejections of Depo Provera stemmed from alarming laboratory studies showing significant cancer risks in animals exposed to the drug.
When Upjohn Company first sought FDA approval in 1967 for the drug Depo Provera as a contraceptive, researchers discovered beagles receiving the drug developed an elevated risk of breast cancer, leading to FDA rejections in 1978 and 1983 despite its availability in other countries.
Many experts disagreed with the FDA rulings, arguing that the evidence of increased breast cancer came from studies conducted on beagle dogs, not humans, and that the FDA’s own advisory committees had recommended approval.
Legal developments in the Depo Provera regulation include, but are not limited to:
The 2024 emergence of research linking the birth control shot to brain tumors has created new concerns about the long-term safety of this contraceptive method.
A March 2024 study published in the BMJ found that prolonged use of Depo Provera for more than one year was associated with a 5.6-fold increased risk of intracranial meningioma requiring surgery.
The relationship between hormonal contraceptives and brain tumors continues to undergo scientific scrutiny as researchers seek to understand the mechanisms behind these findings.
The implications extend beyond contraception since the hormone is also used for treating endometriosis and other conditions, highlighting the broader relevance of these safety concerns across multiple treatment contexts where synthetic progestins are employed.
Depo Provera lawsuits are being filed by individuals across the country who suffered serious bone density loss and other health complications after receiving the contraceptive injection.
TruLaw is currently accepting clients for the Depo Provera lawsuit.
A few reasons to choose TruLaw for your Depo Provera lawsuit include:
If you or a loved one has suffered health problems after receiving Depo Provera injections, you may be eligible to seek compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation that can determine if you qualify for the Depo Provera Lawsuit today.
Depo Provera was banned by the FDA in 1978 as a contraceptive method due to serious concerns about its potential carcinogenic effects and other harmful side effects.
Studies in animals had shown possible links to cancer, prompting regulatory action to protect women’s health while further research was conducted.
Although banned as a contraceptive in the US in 1978, Depo Provera manufacturers continued to produce the drug for other medical purposes.
It remained controversial as international organizations like the World Health Organization and International Planned Parenthood Federation still endorsed its use in developing countries despite the US ban.
The primary concerns that led to Depo Provera’s 1978 ban included potential carcinogenic effects, bone density loss, and reproductive health issues.
The FDA determined these risks were significant enough to halt its approval as a contraceptive until further safety data could be collected and analyzed.
Recent medical research has revealed a possible connection between Depo Provera use and an increased risk of developing meningiomas, a specific type of brain tumor.
Women who used Depo Provera or its generic versions have shown significantly higher rates of these tumors, adding to the concerns about its long-term safety.
Depo Provera carries a black box warning because extended use may reduce bone mineral density.
The warning states that it’s unknown if DMPA use during adolescence increases the risk for osteoporotic fractures later in life, and cautions that use beyond 2 years should only be considered if other contraceptive methods are inadequate.
After being banned as a contraceptive in 1978, Depo Provera was eventually approved by the FDA in 1992 as a contraceptive injection.
The approval came after additional studies and data collection, though the medication continues to generate controversy due to ongoing concerns about its safety profile and side effects.
Managing Attorney & Owner
With over 25 years of legal experience, Jessica Paluch-Hoerman is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share the most reliable, accurate, and up-to-date legal information with our readers!
You can learn more about the Depo-Provera Lawsuit by visiting any of our pages listed below:
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Depo Provera Lawsuit claims are being filed by individuals who allege they developed meningioma (a type of brain tumor) after receiving Depo-Provera birth control injections.
A 2024 study found that women using Depo-Provera for at least 1 year are five times more likely to develop meningioma brain tumors compared to those not using the drug.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?